乳腺癌肉瘤1例报道及文献复习

目的探讨乳腺癌肉瘤的临床病理学特征及其鉴别诊断。方法对1例乳腺癌肉瘤进行组织病理学和免疫表型观察并复习文献,了解该肿瘤的特征。结果镜检显示病变边界清楚,以软骨肉瘤为主,其边缘有少量分化较差的浸润性导管癌成分。免疫表型：软骨肉瘤细胞vimentin强阳性,S-100蛋白阳性,ER、PR,c-erbB-2和CK（AE1／AE3）均阴性;癌细胞CK（AE1／AE3）、ER、PR及c—erbB—2均阳性,vimenfin、S—100蛋白阴性。结论原发于乳腺的癌肉瘤较罕见,诊断需与乳腺恶性分叶状肿瘤以及软组织肉瘤鉴别。     

乳腺富糖原透明细胞癌临床病理特点

目的 探讨乳腺富糖原透明细胞癌的临床病理特点和鉴别诊断要点.方法 观察11例乳腺富糖原透明细胞癌临床病理和免疫组化标记结果,并复习相关文献.结果 患者发病年龄31～73岁,中位48岁.临床均表现为乳腺实性肿块,全部行改良根治术,经随访3～52个月,病人均健在,无复发和远处转移.乳腺富糖原透明细胞癌形态学特点:癌细胞为多边形或柱状,细胞边界清楚,可排列成巢状、片状或乳头状,超过90%的癌细胞胞质透明,其内富含糖原,PAS染色( ).免疫组化染色显示:癌细胞CK( ),CEA、NSE、S-100蛋白、actin、vimentin均(-),约50%病人ER、PR( ).结论 乳腺富糖原透明细胞癌是一种少见的特殊型乳腺癌,其诊断主要依靠组织病理学和免疫组化标记,生物学特性有待于进一步观察.     

乳腺纤维瘤病12例临床病理学观察

目的 探讨乳腺纤维瘤病的临床病理学特征.方法 回顾性分析12例乳腺纤维瘤病临床病理资料,总结其临床、组织学特点并复习相关文献.结果乳腺纤维瘤病由梭形细胞和胶原纤维构成.梭形细胞为增生的纤维母细胞和肌纤维母细胞,构成束状交错形态,瘤细胞呈特征性"指样突起"浸润病灶周围的乳腺组织.瘤细胞vimentin和SMA阳性,Calponin、desmin少数细胞阳性,CK(AE1/AE3)、ER、PR、p63、CK5/6、CD34和S-100蛋白均阴性,Ki-67增殖指数<5%.结论乳腺纤维瘤病为少见的乳腺肿瘤,由增生的纤维母细胞、肌纤维母细胞和胶原纤维共同组成.结合临床特点、钼靶和超声检查也与乳腺癌难以区分,诊断主要依靠病理组织切片,在形态上应注意与乳房的其他梭形细胞病变鉴别.     

乳腺纤维瘤病样梭形细胞癌临床病理分析

目的 探讨乳腺纤维瘤病样梭形细胞癌（fibromatosis-like spindle cell carcinoma,FLSCC）临床病理特征。方法 对3例FLSCC病例进行光镜观察和免疫组化染色[CK、CK（34βE12）、vimentin、SMA、ER、PR、Ki-67、c-erbB-2]。结果 3例均为女性,年龄分别为47、53、56岁,均可触及乳腺肿块。肿瘤境界清楚,但镜下边缘呈浸润性。肿瘤主要是梭形细胞、多边形细胞、少量的管状腺体及鳞上皮巢混合,间质纤维明显增生伴胶原化,细胞成束状排列或散在分布,似纤维瘤病样改变。梭形细胞分化良好,异型性不明显,部分区域细胞较丰富,其间聚集的上皮簇或片状多边形细胞核有轻度异型,可见少数核分裂象。多边形细胞与梭形细胞有移行。病变中亦可见淋巴细胞、浆细胞聚集浸润。上皮细胞、多边形细胞及部分梭形细胞CK（34βE12）、CK（AE1／AE3）阳性,CK阴性的梭形细胞表达vimentin、SMA。3例均行肿块切除,其中1例,术后4个月复发,再行乳腺根治术。结论 乳腺（纤维瘤病样）梭形细胞癌是一种少见的、低度恶性肿瘤,诊断需依赖免疫组化标记并与乳腺其它梭形细胞肿瘤相鉴别。     

乳腺浸润性筛状癌的临床病理及免疫表型

目的 探讨乳腺浸润性筛状癌（invasive cfibriform carcinoma,ICC）的临床病理及免疫表型特点。方法 收集6例ICC的临床资料,观察它们HE形态,并进行免疫组化检测,选用的-抗有CK5、CK（34βE12）、CK8、S-100蛋白、SMA、CD10、ER、PR、c-erbB-2、CgA、PCNA、E-cad。结果 本研究将ICC分为两组：经典型和混合型。它们具有以下特征：①以浸润性筛状结构占优势,细胞排列成浸润性的有棱角的岛屿状,筛孔较不规则。肿瘤细胞小,呈低或中级核级,核分裂象罕见。在多数癌巢周围有反应性纤维母细胞性间质增生。②免疫表型：肌上皮标记（S-100蛋白、SMA、CDl0）及cK（34βE12）肿瘤细胞巢均阴性,而个别肿瘤累及的TDLU周围部分肌上皮标记阳性;激素受体（ER、PR）均阳性;c-erbB-2阴性,PCNA、E-cad呈不同程度的阳性;CgA均阴性。③临床资料：经典型ICC年龄均值较混合型ICC大,肿块大小较混合型ICC小,病程较混合型ICC短,腋窝淋巴结转移少见,转移灶仍保持筛状结构。结论 ICC有其独特的组织学特征及免疫表型,是一种独立的临床病理类型。     

实性乳头状肾细胞癌1例的免疫表型和细胞遗传学特征

目的 探讨乳头状肾细胞癌(papillary renal cell carcinoma,PRCC)实性亚型的病理特点、免疫表型、细胞遗传学特征及鉴别诊断.方法 对1例实性型PRCC行HE染色观察其组织病理学特征,采用免疫组化EnVision法染色和FISH技术分别观察其免疫表型和细胞遗传学改变,并对5例经典型PRCC进行了相应的检查分析以作阳性对照.结果 组织学上,肿瘤由致密的实性片状、小管状结构伴局灶假囊状结构组成,乳头状结构不明显.肿瘤细胞中等大小,立方状或矮柱状,部分呈鞋钉样突向囊外侧,胞质少,嗜酸性,核圆形、卵圆形或略不规则形,Fuhrman核分级为2级.免疫表型和细胞遗传学特征与经典型PRCC相似,肿瘤细胞均表达Ckpan、CK7、CK19、P504S、CD10及vimentin,而WT1、RCC、S-100均不表达.FISH检测显示肿瘤细胞核3号、7号、17号染色体扩增.结论 PRCC实性亚型具有独特的组织形态、免疫表型和细胞遗传学特征与经典型PRCC相似,免疫组化和FISH检测结果有助于明确诊断.     

乳腺肌上皮癌3例临床病理特征分析

目的探讨乳腺肌上皮癌的临床表现、组织形态学改变和免疫表型特征。方法采用HE及免疫组化Leica BOND-MAX全自动染色仪Bond Polymer Refine Detection法,对3例乳腺肌上皮癌进行染色,并复习相关文献。结果乳腺肌上皮癌的癌组织多由梭形细胞组成,部分病例可见上皮样细胞、浆样细胞和透明细胞,呈实性片状、肺泡样、条索状排列;核分裂象易见;无坏死;可发生腋窝淋巴结转移。免疫表型:3例均表达CK、EMA、CD10、p40、actin、Calponin、p63;2例表达CK5/6、CK14、SMA;1例表达S-100蛋白、D2-40、CAM5.2;CD117、CD34、ER、PR、C-erb B-2/HER-2和desmin均不表达;Ki-67增殖指数为10%~20%。结论肌上皮癌细胞形态多样,结合免疫组化组合标记可做出明确诊断,治疗方式以乳腺癌根治术为主。     

乳腺伴梭形细胞化生腺癌2例及文献复习

目的 探讨乳腺伴梭形细胞化生腺癌的临床病理特点及鉴别诊断要点。方法 复习2例乳腺伴梭形细胞化生腺癌的临床资料,并行免疫组化标记。结果 组织学特点：癌组织由梭形细胞构成,细胞异型不明显,核分裂象不多,呈片巢状、条索状、编织状排列,梭形细胞内可见腺癌的管状成分。免疫组化染色显示：癌细胞呈上皮性免疫表型,CK(pan)、EMA阳性,ER、PR、C—erbB-2常阴性,不表达S-100蛋白、desmin和vimentin。结论 乳腺伴梭形细胞分化的腺癌是上皮性特殊性乳腺癌中乳腺化生性癌的1种,其诊断主要依靠组织病理学及免疫组化标记。     

乳腺Paget病细胞角蛋白-8、c-erbB-2、雌激素受体和孕激素受体的表达及意义

目的探讨乳腺Paget病中细胞角蛋白-8(CK-8)、c-erbB-2、雌激素受体(ER)和孕激素受体(PR)的表达及意义。方法对12例乳腺paget病组织进行免疫组织化学染色,检测CK-8、c-erbB-2、ER、PR在Paget细胞与同一例深部癌组织中表达的异同。结果Paget细胞CK-8表达阳性率为100%、c-erbB-2表达阳性率为91.67%,而ER、PR表达阳性率为16.67%。CK-8、c-erbB-2、ER及PR中每一标记物在Paget细胞和同一病例深部癌组织中阳性表达一致。结论乳腺Paget病内Paget细胞来源于乳腺深部存在的导管内癌或浸润性导管癌,是深部癌细胞在表皮内的扩散。     

乳腺实性乳头状癌11例临床病理分析

目的探讨乳腺实性乳头状癌的临床病理学特点、免疫表型。方法对11例乳腺实性乳头状癌的临床病理学特点、免疫表型及淋巴结转移情况进行分析。结果 11例实性乳头状癌均为女性,8例为原位癌,3例伴浸润癌成分,平均年龄63.2岁。11例实性乳头状癌均表现为乳腺肿块,其中3例为乳头溢血。所有病例大体界限清楚,肿瘤细胞围绕纤细的纤维血管轴心呈实性结节状增生,肿瘤细胞形态单一,核染色质细腻,核分裂象5个/10 HPF,8例可见细胞内外黏液。免疫表型:ER、PR均弥漫强阳性,CK5/6和HER-2均阴性,5例在瘤巢周围可见稀少的p63阳性细胞,4例瘤巢周围可见CK5/6和CD10阳性细胞,3例伴浸润癌成分者,瘤巢周围无p63、CK5/6、CD10阳性细胞;5例表达神经内分泌免疫标记Syn,6例表达Cg A。9例行腋窝淋巴结清扫术,其中1例发生淋巴结转移。结论乳腺实性乳头状癌是一种少见的好发于老年女性的乳腺癌,以肿瘤细胞排列呈实性乳头状结节为特征,常有细胞内外黏液分泌,为腺腔A型乳腺癌的免疫表型,并表达神经内分泌免疫标记,预后良好,较少发生腋窝淋巴结转移。     

CD109 expression in basal-like breast carcinoma

Breast cancer can be classified into several subtypes based on gene expression profiling. Basal-like breast carcinoma (BLC) has a triple negative phenotype, that is, the subtype lacks the estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2). It has been recently reported that CD109, a glycosylphosphatidylinositol (GPI)-anchored cell surface protein, is a new breast myoepithelial marker. In the present study CD109 expression was investigated in invasive ductal carcinomas (IDC) of the breast on immunohistochemistry. Eighty-eight formalin-fixed, paraffin-embedded breast carcinoma sections were immunostained with anti-CD109, anti-cytokeratin 5/6 (CK5/6), anti-calponin, anti-vimentin and anti-p63 antibodies. CD109 expression was detected in 18 of 30 basal-like breast carcinomas (BLC) but not in other types of 53 IDC (non-BLC) that were positive for ER, PgR and/or HER2. The percentage of CD109-positive tissues (60%) in BLC was similar to that of CK5/6 (63%) and higher than that of other myoepithelial markers including p63 (23%), calponin (33%) and vimentin (33%). Statistical analysis indicated that the CD109-positive group in BLC, but not the CK5/6-positive group in BLC, was associated with reduced fat invasion ( P  < 0.05). These findings indicate that CD109 is a useful diagnostic marker for BLC and that CD109 expression may affect biological properties of cancer cells.     

Clear cell carcinoma of the breast with solid papillary pattern: a case report with immunohistochemical profile

Glycogen rich clear cell carcinoma of the breast is a rare neoplasm with different morphological characteristics to ordinary breast carcinomas. However, it has some common features with clear cell carcinomas of other organs. This report describes a case of clear cell carcinoma of the breast with a solid papillary pattern centrally localised in the left breast of a 45 year old woman. Antibodies directed against cytokeratin 7 (CK7), CK10, CK14, CK17, CK18, CK19, CK20, CK5/6/18, CK8/18, high molecular weight cytokeratin AE3, high molecular weight cytokeratin 34betaE12, the oestrogen receptor, the progesterone receptor, chromogranin, S-100 protein, smooth muscle actin, vimentin, and carcinoembryogenic antigen were applied to analyse the immunophenotypical profile of this rare neoplasm.     

Oncocytic carcinoma of the breast: frequency, morphology and follow-up

Oncocytic breast carcinomas are tumors composed of no fewer than 70% of oncocytic cells (World Health Organization). The purpose of this study was to determine the frequency, morphologic, immunohistochemical, and clinical features of invasive oncocytic carcinoma in a large series. Twenty-eight cases of putative oncocytic breast carcinoma (selected cases group) and 76 consecutive cases of invasive breast carcinoma (consecutive cases group) were analyzed. Immunohistochemistry for mitochondria, gross cystic disease fluid protein 15, chromogranin, estrogen receptor, progesterone receptor, androgen receptor, HER2/Neu, cytokeratin 7, cytokeratin 14, epithelial membrane antigen, and differentiation cluster 68 was performed. Score for mitochondria was based on intensity and percentage of immunopositive cells. Classes were as follows: (1) oncocytic carcinoma: at least 70%, 3+; (2) mitochondrion-rich carcinoma: 50% to 70%, 3+, or more than 50%, 2+; and (3) all the other cases were referred to as invasive breast carcinoma. Ultrastructural examination was available for 6 cases of oncocytic carcinoma. Morphologic and immunohistochemical features of the 3 groups were compared using Fisher exact test (P < .05). For overall survival analysis, Kaplan-Maier curves were compared using log-rank and Wilcoxon tests (P < .05). Our results suggest that oncocytic breast carcinoma is a morphologic entity with distinctive histologic and ultrastructural features. Mitochondrion-rich carcinomas are histologically similar to oncocytic carcinomas and constitute 19.7% of all invasive carcinomas, indicating that cytoplasmic eosinophilia in breast cancer cells is often due to accumulation of mitochondria. Oncocytic carcinomas and mitochondrion-rich carcinomas are more often grade III tumors and show human epidermal growth factor receptor 2 overexpression. Clinical features and overall survival of oncocytic carcinomas are not distinctive because they are similar to those of the other cases when matched for grade and stage.     

BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis

CXCR5, the receptor for B lymphocyte chemoattractant (BLC), is required for normal development of Peyer's patches, inguinal lymph nodes, and splenic follicles. To test the in vivo activity of BLC in isolation of other lymphoid organizers, transgenic mice were generated expressing BLC in the pancreatic islets. In addition to attracting B cells, BLC expression led to development of lymph node-like structures that contained B and T cell zones, high endothelial venules, stromal cells, and the chemokine SLC. Development of these features was strongly dependent on B lymphocytes and on lymphotoxin alpha1beta2 and could be reversed by blocking lymphotoxin alpha1beta2. These findings establish that BLC is sufficient to activate a pathway of events leading to formation of organized lymphoid tissue.     

Neuronal localization of m1 muscarinic receptor immunoreactivity in the rat basolateral amygdala

Muscarinic cholinergic neurotransmission in the basolateral nuclear complex (BLC) of the amygdala is critical for memory consolidation in emotional/motivational learning tasks. Although knowledge of the localization of muscarinic receptor subtypes in the BLC would contribute to an understanding of the actions of acetylcholine in mnemonic function, previous receptor binding and in situ hybridization studies lacked the resolution necessary to identify which neurons in the BLC express different receptor subtypes. In the present study immunohistochemistry was used to study the neuronal localization of the m1 receptor. The intensity of m1 immunoreactivity varied in different nuclei of the amygdala, and was most robust in the BLC, and in the adjacent posterolateral cortical nucleus. The density and morphology of labeled neurons in the BLC suggested that the m1+ neuronal population included pyramidal cells, the principal neurons in this amygdalar region. In addition, there was dense punctate m1 immunoreactivity in the neuropil of the BLC. Dual labeling immunofluorescence studies of the BLC using antibodies to cell type specific markers were performed to more definitively determine the phenotype of m1-positive (m1+) neurons. An antibody to calcium/calmodulin protein kinase II (CaMK) was used to label pyramidal cells, whereas an antibody to glutamic acid decarboxylase was used to label interneurons. Virtually all of the intensely labeled m1+ neurons of the BLC were CaMK+ pyramidal cells. These data suggest that the ability of M1 receptor antagonists to impair memory consolidation in the BLC is mainly due to blockade of cholinergic influences on the activity of pyramidal neurons.     

Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype

The biology and pathomechanism of bilateral breast cancers is not fully understood. We compared the morphological and immunohistochemical characteristics of primary tumors in patients with synchronous bilateral breast cancers and metachronous bilateral breast cancers, with special focus on intrinsic tumor phenotype. Methods: Tumor morphology and expression of 8 immunohistochemical markers were assessed in tissue microarrays containing primary breast tumor cores from 113 metachronous bilateral breast cancers and 61 synchronous bilateral breast cancers. Analyzed markers included hormone receptors (estrogen receptor, progesterone receptor), HER2, Ki67, cytokeratin 5/6, E-cadherin, vimentin and epidermal growth factor receptor. Cutoff levels are provided in the table. Results: Metachronous bilateral breast cancers tumors had lower estrogen receptor expression (p=0.047) and higher expression of cytokeratin 5/6 (p=0.017) and of vimentin (p=0.008); in multivariate analysis only vimentin retained the significance (p=0.01). Ten (13%) and 11 (26%) of metachronous bilateral breast cancers and synchronous bilateral breast cancers had luminal A phenotype, 39 (50%) and 15 (36%) were luminal B HER2-negative, 13 (17%) and 12 (28%) - luminal B HER2-positive, 3 (4%) and 2 (5%) - HER2-positive (not luminal), and 12 (16%) and 2 (5%) had triple negative phenotype (p=0.07). Conclusion: Metachronous bilateral breast cancers, compared to synchronous bilateral breast cancers, are characterized by more aggressive phenotype, expressed by lower expression of estrogen receptor and stronger expression of cytokeratin 5/6 and vimentin; this does not, however, translate into differences in the distribution of intrinsic tumor phenotypes.     

Pleomorphic carcinoma of the breast with expression of macrophage markers: report of two cases

Pleomorphic ductal carcinoma of the breast is a rare variant included in the morphological group of infiltrating ductal carcinoma. The pleomorphic carcinoma is composed predominantly of epithelial and multinucleated tumor giant cells. We report here two cases presenting a lesion composed microscopically of a proliferation of large pleomorphic cells with a predominance of multinucleated giant cells. These lesions were negative for estrogen receptor, progesterone receptor and Her2-neu (triple-negative phenotype). Basal markers (cytokeratin 5/6, cytokeratin 17 and epidermal growth factor receptor [EGFR]) were present, accompanied by the presence of histiocyte marker CD163 in most neoplastic giant cells. High-grade pleomorphic breast carcinomas with the triple-negative phenotype and expression of basal markers might be included in the basal subtype. This is the first report about the co-expression of macrophage marker CD163, with tumor (P53) or epithelial markers (CAM5.2), as indicated by double immunohistochemistry in pleomorphic ductal carcinoma of the breast.     

Stages on the way to breast cancer

Pathways to breast cancer have been difficult to define using morphology alone. Although epithelial hyperplasia of usual type (HUT) is associated with moderately elevated breast cancer risk, molecular evidence placing it in a cancer precursor pathway is not clear-cut. Recent evidence suggests that small numbers of cytokeratin 5/6 positive cells are precursors of separate lineages which acquire either cytokeratin 8/18/19 or smooth muscle actin (SMA) and cytokeratin 14 on separate pathways to fully differentiated epithelial and myoepithelial phenotypes (and may ultimately lose cytokeratin 5/6 expression). Immunohistochemistry shows that most HUT have a mixed precursor phenotype resembling normal breast with co-expression of cytokeratin 5/6, 8/18/19 and SMA, in contrast to atypical ductal hyperplasia (ADH) and ductal carcinoma in situ which typically have a 'mature' luminal phenotype positive for cytokeratin 8/18/19 but lacking cytokeratin 5/6 expression. While this supports the idea of a biological discontinuity between HUT and ADH/DCIS, caution is called for in the diagnostic use of these reagents until greater experience has been accumulated, and other published data do show features of HUT intermediate between normal breast lobules and ADH.     

乳腺实性乳头状癌73例临床病理诊断

目的对乳腺实性乳头状癌(solid papillary carcinoma,SPC)的临床病理特征和免疫表型特点、预后和鉴别诊断进行探讨。方法收集伴或不伴有浸润癌的SPC共73例,总结其临床资料、大体和组织病理特征,并行透射电镜观察及免疫组织化学EnVision法染色。选用抗体包括CK、肌上皮标记、神经内分泌标记、增殖标记Ki-67和ER、PR、c-erbB-2等。结果本病好发于老年女性,发病平均年龄64.7岁。肿瘤最常见的临床症状为乳腺肿块和乳头溢液。行腋窝淋巴结清扫术43例中有31例检出癌转移。镜检所有标本均见到实性乳头状病变,25例伴有黏液分泌。周边常可伴有导管内乳头状瘤。肿瘤细胞呈多边形、卵圆形或梭形,呈印戒样。胞质丰富,呈嗜酸性或细颗粒状。细胞核轻度或中度异型,51例核分裂象5个/10HPF。43例伴发浸润癌。肿瘤基底型CK表达呈阴性。平滑肌肌动蛋白SMA、p63在乳头轴心肌上皮的阳性率分别为91.8%、67.1%,在导管周围肌上皮的阳性率分别为91.8%,73.9%。CgA和Syn以及NSE阳性率分别为89.0%,86.3%,95.9%。Ki-67平均阳性指数为10.2%。73例行ER、PR染色的肿瘤大部分呈阳性,Her-2大部分呈阴性。电镜下可见到细胞内的神经内分泌颗粒。结论乳腺SPC是一种低度恶性的乳腺导管内癌,好发于老年女性,有其独特的组织形态、免疫组织化学特征,部分SPC与乳腺黏液癌和神经内分泌癌相关。随访资料显示SPC具有良好的预后。     

Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas

Bone is one of the most common sites of distant metastasis for breast carcinomas. In this study, our objective is to identify molecular markers and molecular subtypes that may predict patients at higher risk of developing bone metastasis. Immunohistochemical analysis with antibodies against estrogen receptor α, progesterone receptor, androgen receptor, Her2/neu, epidermal growth factor receptor, CK5/6, CK14, CK17, CK8, and CK18 was performed on representative sections of 21 breast carcinomas with bone metastasis and 94 cases without bone metastasis. The expression rates of receptors, subtype distributions (basal versus nonbasal) of 3 molecular classifications (cytokeratin, triple negative, and cytokeratin/triple negative), and 5 subtypes of cytokeratin/triple negative classification were compared between these 2 groups. We found that (1) the breast cancers with bone metastasis were associated with a significant percentage of estrogen receptor–positive/progesterone receptor–negative tumors compared with tumors without bone metastasis (38% versus 6%, P < .0001). (2) There was significant difference on estrogen receptor expression between high grade and non–high grade in tumors with or without bone metastasis (P = .0084 and 1.0000, respectively). (3) The breast cancers with bone metastasis were more likely to be estrogen receptor positive (85%) and androgen receptor positive (95%) compared with those without bone metastasis (59% and 74%, respectively, both P < .05). (4) There was no significant difference between tumors with or without bone metastasis in subtype distribution (basal versus nonbasal) among all 3 molecular classifications. (5) Luminal B carcinomas of cytokeratin/triple negative classification tended to be associated with bone metastasis but not to a statistically significant extent. In conclusion, bone metastasis is strongly associated with estrogen receptor–positive/progesterone receptor–negative tumors. Significant difference in estrogen receptor expression between high-grade and non–high-grade tumors with bone metastasis suggests that different panels of molecular markers should be used to predict bone metastasis in these 2 groups of tumors.